Background: Neonatal lupus erythematosus (NLE) is an autoimmune syndrome caused by transplacental transmission of maternal autoantibodies, often with devastating consequences.
Introduction
Neonatal lupus erythematosus (NLE) is an autoimmune syndrome caused by transplacental transmission of maternal antibodies, mainly anti SS-A/Ro and anti SS-B/La antibodies, and binding of these antibodies to fetal tissues [1, 2] . Anti SS-A/Ro (60 kDa Ro, 52 kDa Ro or calreticulin) and anti SS-B/La are responsible for direct toxic effects on the myocardium and other organs, when transferred from mother to fetus [3, 4] . The risk for congenital heart block (CHB) is ~ 1-2 %, in cases of maternal positivity for anti SS-A/Ro and/or anti SS-B/La antibody, but rises to amost 18% in cases with a history of CHB in a prior pregnancy (Brito-Zeron, Izmirly, Ramos-Casals, Buyon, & Khamashta, 2015) [5] . The presence of anti SS-A/Ro and anti SS-B/La antibodies is necessary but not sufficient to cause CHB and the complete NLE syndrome, as environmental and fetal factors seem to play an additional role [6] [7] [8] . Interestingly, at the time of NLE diagnosis, the majority of mothers do not have a prespecified rheumatic condition [9] . In the remaining patients, systemic lupus erythematosus (SLE), Sjögren's syndrome, rheumatoid arthritis and undifferentiated connective tissue disease are most often seen [9, 2] .
Most data regarding NLE to date originate from observational studies and case reports/case series. Detailed data about the differences in geoepidemiology, frequency of organ manifestations other than CHB, situations that may be associated with recurrent NLE, and whether various therapeutic modalities affect the clinical outcome, are scarce.
The objective of this systematic literature review was to analyze, on a patient-by-patient basis, the demographic data and geoepidemiology, maternal history traits, clinical and serological characteristics associated with NLE.
Methods
We performed a systematic literature review of the Pubmed/MEDLINE database covering papers from studies published during the time period from 1976 to August 2015. Relevant publications were sought using the MeSH terms "neonatal lupus" or "congenital heart block".
Included publications were restricted to studies in humans and articles in English language. To be included in the review, articles of any type (original articles, case series and case reports) which reported on infants with NLE on an individualized (ie., patient-by-patient) basis, for example giving information about the presence or absence of each component of NLE, were selected. Articles that did not include individual patient information (ie,.reported on frequency/percentage of characteristics in groups of patients) were excluded, because this kind of information could not be subject to further comparative analyses. Review articles, editorials, randomized clinical trials, systematic reviews and letters were also excluded.
The initial selection process was based on titles and abstracts of retrieved articles, followed by full-text review of articles that were considered relevant. We documented the following variables: maternal age at NLE occurrence, connective tissue disease of the mother (if any) and disease duration, treatments received before and during pregnancy, gestational age at NLE diagnosis, organ manifestations of NLE, type and timing of CHB occurrence, treatments administered for CHB, type of delivery, and mortality. The literature search was performed by AE, article selection and data extraction were conducted by all authors collaboratively.
Because not every study reported all characteristics and outcomes of interest for this study, for each characteristic, a number in brackets is given (n=...), referring to the total number of patients for whom these data were available in the original studies.
The study protocol was approved by the Local Research Ethics Committee.
Statistical analysis
All statistical analyses were performed using SPSS software, version 21 (IBM Corporation, Armonk, NY, USA). Continuous variables were tested for normality of data distribution, using the Kolmogorov-Smirnov test, and were expressed as mean (standard deviation, SD) and median (minumum-maximum, min-max) values, in case of normally and non-normally distributed or ordinal data, respectively. Categorical variables were reported as frequencies (percentages) and were compared with the chi-square test. A p-value <0.05 was considered significant for all comparisons.
Results
A total of 1125 abstracts of articles were evaluated. After excluding articles other than case reports/series and original articles and overlapping patients in case reports or original articles, the full text for 267 original articles/case reports were evaluated. Following full text evaluation, a total of 69 papers were excluded: 7 case reports and 15 original articles because of irrelevance, Table 1 ].
Clinical manifestations of the NLE syndrome and differences in geoepidemiology
We identified a total of 755 cases of NLE from all of the included studies. At the time of NLE diagnosis, the mean (SD) age of mothers was 29.7 (4.8) years, and a little over one third (36%) were nulligravidae ( Table 2 ). The most frequently reported clinical manifestations of NLE were CHB (492 patients, 65.2%), cutaneous lupus (250 patients, 33.1%) and cytopenias 117 (15.5%). Hepatic, pulmonary and neurologic complications were less frequently reported (≤ 10% each) ( Table 3 ). The majority of cases with NLE (any manifestation) were diagnosed postnatal (n=357, 58%); however, in cases of cardiac involvement/CHB, the diagnosis was made during pregnancy in 72.1% (n=256). Maternal age was not different between NLE cases with and without CHB [mean (SD) age 29.9 (4.4) vs. 29.0 (5.6) years, for cases with and without CHB development, respectively, p=0.19).
We observed differences in the frequency of the different clinical manifestations of the NLE syndrome, depending on the country of origin of the original studies (Table 4 ). Interestingly, CHB was much more frequently reported in patients of European or American descent (49.4% (243/492) and 35% (172/492), respectively), while reports originating from countries of Asia reported a higher incidence of skin involvement (45.2% [113/250]) ( Table 5 ).
In only 36% of cases (n=272), the autoantibody status of infants was assessed by investigators ( Table 3) . Presence of anti-SSA, anti-SSB and anti-RNP, either alone or in some combination thereof, was detected in 82.7%, 46.3% and 9.1%, respectively; of note, in 20 cases (7.3%), no serum autoantibody could be detected. These seronegative infants did not differ significantly in terms of organ manifestations, week of diagnosis, survival rate or implantation of pacemaker from infants with autoantibodies.
Timing of CHB detection and which women are at risk? Maternal autoantibody status and disease in CHB
The status of maternal autoantibodies with CHB was reported in 376 mothers (76.4%) ( Table   6 ). Anti Mean (SD) gestational age at the time of detection in cases with CHB (n=492 total) was 23.8 (4.5) weeks. Almost ¾ of cases (72.9%) with CHB were diagnosed between the 18th and 26th
week of gestation; however, we found four cases (2.2%) diagnosed at weeks 16-17 and an additional 11.8% (n=22), in which CHB was detected after week 30 of gestation (Table 7) . Of note, less than half of pregnancies (46.1%, n=95) resulted in a term pregnancy, while 20% resulted in at least moderate prematurity (≤ 34 weeks) ( Table 8 ). The majority of cases had type III (ie., complete) atrioventricular block (78.0%, n=231).
For 250 mothers, information on previous gestational history and birth outcome was provided by authors. Among them, 41 (16.4%) had given birth to a baby with NLE in a prior gestation.
Recurrence rate of CHB was 31/250 (12.4%). All mothers with recurrent NLE were autoantibody positive; interestingly, however, while the majority was positive for anti-Ro and/or anti-La (36/39, with available data), three women with recurrent NLE were negative for anti-Ro and anti-La and showed positivity only for ANA. Prevalence of rash was slightly higher in girls (55.8%) and those born at term (69.0%) ( Table 9 ).
Discussion
We have performed a systematic literature review, to characterize the clinical spectrum of the NLE syndrome. Of note, our work focused on studies that provided detailed individual case presentations to understand better maternal and fetal characteristics (issues regarding therapy of NLE are the topic of a separate systematic review). CHB was the most prominent clinical manifestation (65.2% of cases), followed by cutaneous rash and cytopenias (hepatic, pulmonary and neurologic complications were much less frequent). Presence of a maternal autoimmune disease was not a prerequisite for NLE, as in almost one in three pregnancies (31.9%) resulting in NLE, no disease was evident in the mother, Also, while anti-SSA/Ro was expectedly the most frequent autoantibody found in maternal serum, it is noteworthy that, in 10% of mothers (and 7.3% of neonates, accordingly), no circulating autoantibody could be detected in the serum; this observation clearly poses questions regarding the underlying pathophysiology of CHB in these cases.
We separated all NLE cases depending on the country of origin of the study, and respective ethnic and racial distribution of cases, to identify potential differences in disease phenotype. Strikingly, we found that studies originating from Europe or America (mainly the The United States of America) reported significantly higher rates of CHB, the most serious complication of NLE (the risk of mortality ranges between 15% and 20% [10, 11] ), while studies in Asian patients revealed cardiac abnormalities in little over 30% of patients. On the contrary, cutaneous involvement was twice as frequent in studies from Asian countries versus other populations; as an illustrative example, in two studies from Japan and China, more than 80% of the combined 316 patients had cutaneous NLE, while the rate of CHB was 8.9-23% [12, 13] . While it is tempting to speculate about the involvement of genetic or environmental factors underlying this disparity, one must also be aware of the possibility of under-reporting, as well as the absence of a common definition, especially for CHB.
The notion that NLE is a syndrome mediated by the passive transfer of autoantibodies from mother to fetus is widely accepted. Clinical and experimental data support the pivotal role of The pathogenetic role of other autoantibodies, mainly anti-SSB/La and anti-U1RNP, is less clear and further obscured by the fact that, in most circumstances, these autoantibodies coexist with anti-SSA/Ro (in our review, only 15, 25 and one patient were positive only for anti-SSB, only ANA positivity and anti-U1RNP, respectively). In mothers with SLE, ANA trans passes from placenta and works with anti SS-A/Ro to make harm in fetal thyroid tissue and myocardium [1] . Clinicians should consider testing for maternal anti-U1RNP and only ANA positivity in congenital heart block cases in which anti-SSA/Ro and/or anti-SSB/La are negative and there is no structural etiology [14] .
More intriguing is the fact that 10.6% (40/376) of mothers tested were negative for any circulating autoantibody. The possibility of inter-laboratory differences in sensitivity must naturally be taken into account. Moreover, in a recent review, Brito-Zeron et al questioned the existence of "immunonegative" CHB, owing to the fact that most such cases were diagnosed in children in adolescence or mothers who had not been tested for the full panel of potentially cardio toxic autoantibodies [15] . A maternal autoimmune disease is not a prerequisite for the development of NLE. On the contrary, our analysis shows that almost 32% of patients did not suffer from any disease at the time of birth of a child with NLE. Clearly, absence of maternal disease makes the diagnosis of NLE even more challenging because asymptomatic women will usually not be tested for autoantibodies. This highlights the need to test for the latter in all women of reproductive age who present to rheumatology care even for mild, non-specific symptoms.
Our review attempted to capture all data regarding CHB subtypes and detection time in neonates born with NLE. Transplacental transfer of IgG antibodies from mother to fetus starts at 12th gestational week [3, 4] . The period traditionally considered to confer the highest risk is during the middle to late parts of the second trimester, especially between the 16 and 26th weeks [3, 4] .
Indeed, we found that almost ¾ of cases (72.9%) were diagnosed between the 18th and 26th
week of gestation, with a mean gestational age of ~ 24 weeks; however, we also found four cases (2.2%) diagnosed at weeks 16-17 and an additional 11.8% (n=22), in which CHB was detected after week 30 of gestation, spanning a total period of more than 15 gestational weeks.
Withstanding the fact that the majority of infants (78.0%) develop type III (ie. complete) atrioventricular block, the rarity and of its occurrence as well as inability to predict, and the questionable efficacy -at best-of any therapeutic modality, we believe it may not be feasible to recommend strict weekly scheduling of fetal echocardiography throughout this whole period.
Rather, we tend to favor a more practical approach regarding frequency of fetal echocardiography in pregnant women with circulating anti-SSA and/or anti-SSB antibodies, which consists of biweekly examinations for the period 16-28 gestational weeks [2] . This recommendation should by no means serve as a universal guide, but may provide a framework to reduce unnecessary stress on future mothers.
In our study found that anti SSA / Ro antibody positivity was 84.6% and anti-SSB / La antibody positivity was 58.9% in Cutaneous manifestations. On the other hand, Anti U1-RNP antibody is responsible from skin involvement [14] . In our study, anti U1-RNP positivity was 11.5%.
Apart from cardiac involvement, involvement of other organs in the NLE has been much less characterized to date. Outside the skin, we found that hematologic involvement, hepatic dysfunction, pulmonary and neurologic complications, all appear in decreasing order of frequency in neonates with the NLE syndrome (15.5%, 10.3%, 1.3% and 1.2%). Interestingly, pulmonary manifestations showed a predilection for male gender (62.5% of affected neonates were males), in contrast to other system manifestations. Skin lesions, hematologic involvement, hepatobiliary involvement spontaneously disappear by cleaning of antibodies from the circulation of the baby at 6-12. months [16, 2] . We were not able to characterize further the type of manifestations in each of these organ systems, as most of this information was not provided by original studies.
In two studies, recurrence of CHB was seen in 17% of pregnancies after the birth of a child with CHB [17, 18] . Recurrence after first pregnancy was found as 12.1% in another study and all these recurrences were seen in patients with autoantibody (anti-SSA/Ro antibody, and anti-SSB/La) positivity, none of them were autoantibody negative [19] . In our study, none of the mothers with recurrent CHB baby were autoantibody negative. Additionally, percentage of recurrent pregnancy with NLE was 16.4%, CHB was 12.4% and rash was 4%.
Certain limitations of our study deserve acknowledgment. First, due to strict methodologic limitations, we included only published studies which reported data on an individual patient basis. Inevitably, this has led to non-inclusion of studies reporting on groups of patients, as these data could not be similarly analyzed. Moreover, studies included in our systematic review had their own limitations, mainly in terms of missing data. Nevertheless, by including more than 750 patients with available detailed data, our literature review captured most clinical aspects of NLE, as well as intriguing phenotypic differences by race and ethnicity.
In conclusion, we performed a systematic literature review to portray the full clinical spectrum of NLE, beyond its most devastating consequence, autoimmune CHB. The latter is rather rare, and the possibility of its occurrence spans a substantial period within gestation. This, together with the paucity of therapeutic options (which we attempt to summarize in a separate systematic review), warrants a rational screening approach for its detection. 
